Chimeric Antigen Receptor T Cells in Refractory B-Cell Lymphomas.

ABSTRACT:

Background

Patients with diffuse large B-cell lymphoma or follicular lymphoma that is refractory to or that relapses after immunochemotherapy and transplantation have a poor prognosis. High response rates have been reported with the use of T cells modified by chimeric antigen receptor (CAR) that target CD19 in B-cell cancers, although data regarding B-cell lymphomas are limited.

Methods

We used autologous T cells that express a CD19-directed CAR (CTL019) to treat patients with diffuse large B-cell lymphoma or follicular lymphoma that had relapsed or was refractory to previous treatments. Patients were monitored for response to treatment, toxic effects, the expansion and persistence of CTL019 cells in vivo, and immune recovery.

Results

A total of 28 adult patients with

SUBMITTER: Schuster SJ 

PROVIDER: S-EPMC5788566 | biostudies-literature | 2017 Dec

REPOSITORIES: biostudies-literature